Dongfang Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dongfang Wang has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Zemin Zhang
Institute for Data-Driven Tumor Immunology, Chongqing Medical University, Chongqing, China.
17 shared publications - Chang Liu
Peking University 1 Biomedical Pioneering Innovative Center (BIOPIC), Academy for Advanced Interdisciplinary Studies, School of Life Sciences, State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer Beijing, China
15 shared publications - Dan Tong
Changping Laboratory, Beijing, China
15 shared publications - Guohui Dang
Changping Laboratory, Beijing, China
15 shared publications - Hongtao Fan
Peking University 1 Biomedical Pioneering Innovative Center (BIOPIC), Academy for Advanced Interdisciplinary Studies, School of Life Sciences, State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer Beijing, China
15 shared publications - Liangtao Zheng
Analytical Biosciences Limited 6 , Beijing, China
15 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Therapeutic modulation of the vitreoretinal fibrosis microenvironment in female mice using engineered macrophage-derived extracellular vesicles
Vitreoretinal fibrosis, a hallmark of proliferative vitreoretinopathy (PVR) triggered by retinal detachment or ocular trauma, necessitates surgery. Through data mining of the vitreoretinal fibrosis microenvironment in PVR patients and mice, showing elevated transforming growth factor β1 (TGFβ1) and M2 macrophage enrichment, we designed and engineered extracellular vesicles that conferred anti-fibrotic efficacy against PVR. These M1 macrophage-derived vesicles (M1evs) were conjugated with anti-TGFβ1 antibodies (aT) via MMP-cleavable linkers (aT-cl-M1ev, termed ACE). Upon intravitreal injection in female PVR model mice, ACE selectively accumulates in lesions, where released antibodies neutralize TGFβ1 and M1evs inhibit M2 macrophage polarization, modulating the microenvironment to diminish vitreoretinal fibrosis. Further incorporating anti-platelet-derived growth factor receptor antibodies yields aTP-cl-M1ev (ACE Plus ) to prevent retinal detachment progression in advanced-stage PVR, an efficacy validated in a patient-derived PVR membrane xenograft model. Therapeutic modulation of the vitreoretinal fibrosis microenvironment with the ACE platform provides an efficacious alternative to surgery for PVR.
- 25 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessTherapeutic modulation of the vitreoretinal fibrosis microenvironment in female mice using engineered macrophage-derived extracellular vesicles
Vitreoretinal fibrosis, a hallmark of proliferative vitreoretinopathy (PVR) triggered by retinal detachment or ocular trauma, necessitates surgery. Through data mining of the vitreoretinal fibrosis microenvironment in PVR patients and mice, showing elevated transforming growth factor β1 (TGFβ1) and M2 macrophage enrichment, we designed and engineered extracellular vesicles that conferred anti-fibrotic efficacy against PVR. These M1 macrophage-derived vesicles (M1evs) were conjugated with anti-TGFβ1 antibodies (aT) via MMP-cleavable linkers (aT-cl-M1ev, termed ACE). Upon intravitreal injection in female PVR model mice, ACE selectively accumulates in lesions, where released antibodies neutralize TGFβ1 and M1evs inhibit M2 macrophage polarization, modulating the microenvironment to diminish vitreoretinal fibrosis. Further incorporating anti-platelet-derived growth factor receptor antibodies yields aTP-cl-M1ev (ACE Plus ) to prevent retinal detachment progression in advanced-stage PVR, an efficacy validated in a patient-derived PVR membrane xenograft model. Therapeutic modulation of the vitreoretinal fibrosis microenvironment with the ACE platform provides an efficacious alternative to surgery for PVR.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S4. GO enrichment analysis of human LRRC15+ CAFs from lung cancer, based on scRNA-seq data, related to Figure 5C
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S4. GO enrichment analysis of human LRRC15+ CAFs from lung cancer, based on scRNA-seq data, related to Figure 5C
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S4 LRRC15 deficiency induces broad immune alterations in mouse tumors, related to Figure 3
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S4 LRRC15 deficiency induces broad immune alterations in mouse tumors, related to Figure 3
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S2. Summary of scRNA-seq Datasets of Lung Cancer Stromal Cells, related to Figs. 1, 3, 5, S1, S2, and S8
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S2. Summary of scRNA-seq Datasets of Lung Cancer Stromal Cells, related to Figs. 1, 3, 5, S1, S2, and S8
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S1. Clinical information of lung cancer patients, related to Figures 1, 3, 4, 5, S2, S6 and S7
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S1. Clinical information of lung cancer patients, related to Figures 1, 3, 4, 5, S2, S6 and S7
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S8 Targeting LRRC15+ CAFs attenuates tumor progression, related to Figure 6
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S8 Targeting LRRC15+ CAFs attenuates tumor progression, related to Figure 6
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S3 LRRC15 promotes tumor progression by modulating immune responses, related to Figure 2
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S3 LRRC15 promotes tumor progression by modulating immune responses, related to Figure 2
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S5. GO enrichment analysis of mouse LRRC15+ CAFs from TC1-GFP tumor co-injected with TGF-β-treated CAFs, based on scRNA-seq data, related to Figure 5D
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Table S5. GO enrichment analysis of mouse LRRC15+ CAFs from TC1-GFP tumor co-injected with TGF-β-treated CAFs, based on scRNA-seq data, related to Figure 5D
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S2 LRRC15 expression correlates with poor prognosis in cancer patients, related to Figure 1
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S2 LRRC15 expression correlates with poor prognosis in cancer patients, related to Figure 1
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S7 LRRC15 in CAFs promotes macrophage M2 polarization via ECM, related to Figure 5
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression
Figure S7 LRRC15 in CAFs promotes macrophage M2 polarization via ECM, related to Figure 5